Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Yalai Bai"'
Autor:
Kristina A. Fanucci, Yalai Bai, Vasiliki Pelekanou, Zeina A. Nahleh, Saba Shafi, Sneha Burela, William E. Barlow, Priyanka Sharma, Alastair M. Thompson, Andrew K. Godwin, David L. Rimm, Gabriel N. Hortobagyi, Yihan Liu, Leona Wang, Wei Wei, Lajos Pusztai, Kim R. M. Blenman
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract We assessed the predictive value of an image analysis-based tumor-infiltrating lymphocytes (TILs) score for pathologic complete response (pCR) and event-free survival in breast cancer (BC). About 113 pretreatment samples were analyzed from p
Externí odkaz:
https://doaj.org/article/de40aac7a42e4da9b372c3f02f74cceb
Autor:
Michal Marczyk, Tao Qing, Tess O’Meara, Vesal Yagahoobi, Vasiliki Pelekanou, Yalai Bai, Emily Reisenbichler, Kimberly S. Cole, Xiaotong Li, Vignesh Gunasekharan, Eiman Ibrahim, Kristina Fanucci, Wei Wei, David L. Rimm, Lajos Pusztai, Kim R. M. Blenman
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-12 (2022)
Abstract Differences in the tumor immune microenvironment may result in differences in prognosis and response to treatment in cancer patients. We hypothesized that differences in the tumor immune microenvironment may exist between African American (A
Externí odkaz:
https://doaj.org/article/684458edf8ea4c0394edcc581f66fe7d
Autor:
Christina M. Dieli-Conwright, Maura Harrigan, Brenda Cartmel, Anees Chagpar, Yalai Bai, Fang-yong Li, David L. Rimm, Lajos Pusztai, Lingeng Lu, Tara Sanft, Melinda L. Irwin
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract Few trials have examined the effect of lifestyle behavioral interventions on tissue markers in patients with cancer. The purpose of this study was to examine the feasibility and impact of a 6-month weight loss intervention on breast tissue a
Externí odkaz:
https://doaj.org/article/04c7375291ed48a3b7c4754093ccc449
Autor:
Bilal Cakir, Yoshiaki Tanaka, Ferdi Ridvan Kiral, Yangfei Xiang, Onur Dagliyan, Juan Wang, Maria Lee, Allison M. Greaney, Woo Sub Yang, Catherine duBoulay, Mehmet Hamdi Kural, Benjamin Patterson, Mei Zhong, Jonghun Kim, Yalai Bai, Wang Min, Laura E. Niklason, Prabir Patra, In-Hyun Park
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
The study of human microglia function in health and disease is limited by the availability of sound models. Here, the authors develop a method to generate functional microglia in human cortical organoids and investigate the role of human microglia du
Externí odkaz:
https://doaj.org/article/f7e442e71a714aed94079c5c43728648
Autor:
Ioannis Zerdes, Michele Simonetti, Alexios Matikas, Luuk Harbers, Balazs Acs, Ceren Boyaci, Ning Zhang, Dimitrios Salgkamis, Susanne Agartz, Pablo Moreno-Ruiz, Yalai Bai, David L. Rimm, Johan Hartman, Artur Mezheyeuski, Jonas Bergh, Nicola Crosetto, Theodoros Foukakis
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-11 (2021)
Abstract Emerging data indicate that genomic alterations can shape immune cell composition in early breast cancer. However, there is a need for complementary imaging and sequencing methods for the quantitative assessment of combined somatic copy numb
Externí odkaz:
https://doaj.org/article/3346ad4f61b5411594a62c963ed56bb4
Autor:
Thazin Nwe Aung, Saba Shafi, James S. Wilmott, Saeed Nourmohammadi, Ioannis Vathiotis, Niki Gavrielatou, Aileen Fernandez, Vesal Yaghoobi, Tobias Sinnberg, Teresa Amaral, Kristian Ikenberg, Kiarash Khosrotehrani, Iman Osman, Balazs Acs, Yalai Bai, Sandra Martinez-Morilla, Myrto Moutafi, John F. Thompson, Richard A. Scolyer, David L. Rimm
Publikováno v:
EBioMedicine, Vol 82, Iss , Pp 104143- (2022)
Summary: Background: The prognostic value of tumor-infiltrating lymphocytes (TILs) assessed by machine learning algorithms in melanoma patients has been previously demonstrated but has not been widely adopted in the clinic. We evaluated the prognosti
Externí odkaz:
https://doaj.org/article/7801b51303bd44db94554a2be3bdc2d7
Autor:
Julia Foldi, Andrea Silber, Emily Reisenbichler, Kamaljeet Singh, Neal Fischbach, Justin Persico, Kerin Adelson, Anamika Katoch, Nina Horowitz, Donald Lannin, Anees Chagpar, Tristen Park, Michal Marczyk, Courtney Frederick, Trisha Burrello, Eiman Ibrahim, Tao Qing, Yalai Bai, Kim Blenman, David L. Rimm, Lajos Pusztai
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract The goal of this Phase I/II trial is to assess the safety and efficacy of administering durvalumab concurrent with weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide (ddAC) neoadjuvant therapy for stages I–III triple-negativ
Externí odkaz:
https://doaj.org/article/a0cd120873bd4d7189d5d75f4bae0e84
Autor:
Julia Foldi, Andrea Silber, Emily Reisenbichler, Kamaljeet Singh, Neal Fischbach, Justin Persico, Kerin Adelson, Anamika Katoch, Nina Horowitz, Donald Lannin, Anees Chagpar, Tristen Park, Michal Marczyk, Courtney Frederick, Trisha Burrello, Eiman Ibrahim, Tao Qing, Yalai Bai, Kim Blenman, David L. Rimm, Lajos Pusztai
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/f95c42b14d2c4ab49587084764b1c998
Autor:
Yalai Bai, Huan Cheng, Jennifer Bordeaux, Veronique Neumeister, Sudha Kumar, David L Rimm, David F Stern
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e79901 (2013)
HER2/Neu (ErbB-2) overexpression, which occurs in 15-20% of breast cancer cases, is associated with better response to treatment with the drug trastuzumab. PhosphoHER2 (pHER2) has been evaluated for prediction of response to trastuzumab. Both markers
Externí odkaz:
https://doaj.org/article/120a4aeb316c45a5a4f081c211f4e8c9
Autor:
Myrto Moutafi, Charles J. Robbins, Vesal Yaghoobi, Aileen I. Fernandez, Sandra Martinez-Morilla, Vasiliki Xirou, Yalai Bai, Yan Song, Patricia Gaule, Joseph Krueger, Kenneth Bloom, Salisha Hill, Daniel C. Liebler, Regan Fulton, David L. Rimm
Publikováno v:
Laboratory Investigation. 102:1101-1108
The efficacy of the antibody drug conjugate (ADC) Trastuzumab deruxtecan (T-DXd) in HER2 low breast cancer patients suggests that the historical/conventional assays for HER2 may need revision for optimal patient care. Specifically, the conventional a